Last updated: February 12, 2026
Product Overview
NDC 42858-0102 is an immunotherapy drug within the BCG (bacillus Calmette-Guérin) class, primarily used for bladder cancer treatment and certain other indications. Its formulation targets non-muscle invasive bladder cancer (NMIBC) post-resection and is supplied as a lyophilized powder for intravesical instillation.
Market Size and Dynamics
The global bladder cancer therapeutics market was valued at approximately $1.8 billion in 2022. The segment serving NMIBC constitutes roughly 60% of this figure, estimated at a current market size of $1.08 billion.
Key Drivers
- Rising incidence of bladder cancer: about 81,000 new cases in the U.S. annually.
- Adoption of intravesical BCG therapy as a standard of care: current guidelines recommend BCG for high-grade NMIBC, with 20,000 to 25,000 patients in the U.S. receiving intravesical BCG annually.
- Increased awareness and screening: leads to earlier diagnosis and treatment.
- Alternative therapies and vaccine development: threaten volume growth but have gradual adoption pathways.
Market Competition
- Existing BCG formulations: OncoTice (Merck) dominates with approximately 80% market share. Other formulations include ImmuCyst (Fujifilm) and TICE BCG (also Merck).
- Manufacturing constraints: BCG production faces capacity limitations, contributing to supply shortages and potential price volatility.
- Emerging therapies: Checkpoint inhibitors like Pembrolizumab and novel immunotherapies are in late-stage trials but have yet to replace BCG as first-line intravesical therapy.
Pricing Trends
Regulatory and Pricing Policies
- Reimbursement:
Medicare covers intravesical BCG as a reimbursable outpatient service, with reimbursement rates varying by setting and geographic location. Patient out-of-pocket costs typically range between $50 and $200 per course.
- Pricing controls:
Some U.S. states are considering legislation to regulate drug prices, potentially impacting pricing strategies for BCG producers in the future.
Market Entry Considerations
- Generic development: Since BCG's patent expired decades ago, multiple generics exist, contributing to pricing pressure.
- Market barriers: Manufacturing complexities and regulatory approvals restrict entry of new competitors, particularly evident in biologics and live vaccine products like BCG.
Forecast Summary
| Year |
Estimated Price per Treatment Course |
Market Share of New Entrants |
Key Factors |
| 2023 |
$600–$700 |
Low |
Supply shortages, demand |
| 2024 |
$500–$600 |
Moderate |
Capacity expansions |
| 2026 |
$400–$500 |
Increasing |
Market stabilization |
Summary
The current market for NDC 42858-0102 is characterized by stable demand driven by bladder cancer incidence, but constrained by manufacturing limitations leading to volatile pricing. Short-term prices are likely to escalate due to supply shortages, with a gradual decline expected as capacity increases.
Key Takeaways
- The global bladder cancer treatment market is valued at approximately $1.8 billion, with NMIBC therapies comprising a significant portion.
- Prices for BCG formulations have historically ranged from $300 to $550 per course, with recent increases caused by supply constraints.
- Short-term projections indicate prices may reach $600–$700; medium-term, prices could stabilize around $400–$500.
- Manufacturing capacity constraints remain the primary factor influencing pricing volatility.
- Market entry barriers and existing generics limit significant price competition in the near term.
FAQs
1. How does manufacturing capacity influence BCG pricing?
Capacity limitations restrict supply during shortages, pushing prices higher. Expanding manufacturing can alleviate scarcity, leading to price stabilization.
2. Are new therapies expected to replace BCG in bladder cancer treatment?
While some immunotherapies are in late-stage trials, BCG remains the standard due to established efficacy, safety profile, and manufacturing infrastructure.
3. What is the typical reimbursement for BCG treatment?
Patients usually pay between $50 and $200 per treatment course, with Medicare and private insurers covering the majority of costs.
4. Will patent expirations impact BCG pricing?
Yes. Since BCG patents expired decades ago, multiple generics exist, exerting downward pressure on prices.
5. What factors could alter future price projections?
Regulatory changes, manufacturing capacity expansions, the emergence of competing therapies, and policies regulating drug prices can significantly impact prices.
Citations
[1] GlobalData, “Bladder Cancer Therapeutics Market Report,” 2022.
[2] U.S. CDC, “Bladder Cancer Incidence,” 2022.
[3] IQVIA, “Pharmaceutical Pricing Trends,” 2022.
[4] American Urological Association, “Guideline for Non-Muscle Invasive Bladder Cancer,” 2021.
[5] Merck & Co. Annual Reports, 2022.
